Ge Long Hui·2026-01-15 00:31Core Insights - WuXi AppTec (603259.SH/2359.HK) presented at the 44th JPM Healthcare Conference, updating on its business progress [1] Group 1: Business Development - The company’s small molecule API synthesis capacity reached 4 million liters by the end of 2025, indicating a robust commercial supply system built over 25 years [1] - As of Q3 last year, WuXi AppTec's small molecule CDMO pipeline totaled 3,430, with 80 commercial molecules, representing 16% of the global clinical stage small molecule new drugs [1] Group 2: Financial Performance - WuXi AppTec expects a revenue of approximately 45.456 billion yuan for the full year 2025, reflecting a year-on-year growth of 15.84%, with a 21.4% increase in revenue from continuing operations [1] - The company anticipates a significant profit increase, with net profit attributable to shareholders expected to be around 19.151 billion yuan, a substantial year-on-year growth of 102.65% [1] - Adjusted non-IFRS net profit is projected at approximately 14.957 billion yuan, a year-on-year increase of 41.33%, while the net profit after deducting non-recurring items is expected to be about 13.241 billion yuan, up 32.56% year-on-year [1] - The pre-announcement data indicates that WuXi AppTec will achieve historical highs in revenue and the three profit metrics for 2025 [1]